UnionClin has recently signed a Master Service Agreement (MSA) with MEDSIR, a leading oncology-focused CRO headquartered in Spain. The two companies have established a strategic partnership and launched full collaboration in international multi-center clinical development services.

Under the agreement, their first joint program—the Phase II international multi-center clinical trial CADILLAC for advanced breast cancer—has commenced concurrently. UnionClin will lead clinical execution in China, providing end-to-end services covering regulatory affairs, clinical operations, medical affairs, and pharmacovigilance.

UnionClin stated that this collaboration with MEDSIR not only validates the company’s comprehensive capabilities in international clinical research but also lays a solid foundation for securing more overseas clinical projects and advancing its global business expansion.

About UnionClin

Founded in 2017 and headquartered in Shanghai, UnionClin is a specialized contract research organization (CRO) focused on clinical development for innovative drugs in oncology, autoimmune diseases, and neuroscience.

Backed by an AI-powered digital platform, professional clinical resources, and a highly experienced team, UnionClin has built an intelligent end-to-end service system covering the full lifecycle of drug development. From IND strategy to NDA filing, the company provides one-stop solutions for Phase I–III clinical trials.

Its comprehensive service offerings include: Medical Affairs, Clinical Operations, Data Management & Statistical Analysis, Clinical Pharmacology, Pharmacovigilance, Independent Central Imaging Review, Bioanalysis, Site Management Organization (SMO), and specialized professional staffing.

UnionClin possesses proven expertise in dual filings in China and the US, innovative trial design, and global multi-center clinical research services. The company is committed to introducing high-quality overseas assets while accelerating the internationalization of domestic innovative therapies.

With a team of more than 500 professionals, UnionClin operates in over 100 cities across China. It has established strong partnerships with more than 2,000 key opinion leaders (KOLs) and over 1,000 clinical research sites, and has supported more than 400 clinical development programs.